Sentiment Summary
Recent Events
Confirmed corporate spin-off of Hanwha Corp into a surviving Hanwha Corp and a new Hanwha Machinery & Service Holdings entity. The shareholder record date for allocation of spin-off shares is June 30, 2026, with trading suspension scheduled from June 29, 2026 to July 23, 2026.
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
Hanwha Corp confirmed a corporate spin-off that qualifies as a trading issue affecting its own shares. An official Korea Exchange filing states Hanwha shares were scheduled for trading suspension due to the spin-off, with the originally disclosed suspension period running from 2026-06-29 to 2026-07-23 and new shares scheduled to list on 2026-07-24. Subsequent reporting after KRX preliminary relisting approval said the new spin-off company was instead targeting establishment on 2026-08-01 and KOSPI listing on 2026-08-25, indicating the July 28 to August 20 schedule in the claim is not confirmed by the sources reviewed.
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
Q1 2026 earnings release scheduled. Analysts forecast strong results driven by overseas sales growth, which previously caused a 9% stock price increase in April on anticipation scheduled.
Ex-dividend date for the proposed 2025 final dividend of 11.95 CNY per share on 2026-05-12. Medium importance is justified by the dividend yield typically causing a >5% price adjustment, scheduled.
Final dividend of RMB 0.75 per share for fiscal year 2025 is scheduled to go ex-dividend on 2026-05-12. Low importance reflects the typical minor price adjustment on ex-dividend dates, scheduled.
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
Q1 2026 earnings release, for which high importance is estimated due to historical price volatility exceeding 10% following earnings reports, scheduled.
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
Q1 2026 earnings release scheduled.
Designated as a large business group (conglomerate) by the Korea Fair Trade Commission, effective May 1, 2026, due to assets exceeding KRW 5 trillion; this is the first time for a cosmetics ODM company, with medium impact estimated due to increased regulatory oversight scheduled.
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
Announced Q1 2026 results with revenue of KRW 1.58 trillion (-7.1% YoY) and operating profit of KRW 107.8 billion (-24.3% YoY). While down year-over-year, operating profit significantly beat analyst forecasts and marked a return to profitability from the previous quarter's loss.
Announced the cancellation of 315,739 treasury shares, valued at approximately KRW 80.4 billion, for the purpose of enhancing shareholder value. The cancellation is scheduled for May 15, 2026.
Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.
Announced a strategic partnership with Eli Lilly on April 30, 2026, to launch 'C-Lab Outside,' an open innovation center scheduled for completion in July 2027. Analysts forecast a price impact of approximately 5%, forecasted.
Signed a strategic cooperation agreement with DingTalk (an Alibaba company) to upgrade its operations with artificial intelligence applications. This operational partnership is estimated to have a low market impact (≥1%).
The company decided to cancel 293,575 of its own common shares on April 29, 2026, to enhance shareholder value.
An executive vice president is scheduled to announce a long-term revenue target for Cenobamate (Xcopri), aiming for $1 billion in U.S. sales by 2029 at the Bio Korea 2026 event on April 29, 2026; high importance is estimated as the $1B target is a critical valuation milestone for blockbuster status, scheduled.
Announced Q1 2026 results: Revenue KRW 1.22 trillion (+5.0% YoY), Operating Profit KRW 137.8 billion (+6.9% YoY), but Net Income KRW 132.4 billion (-5.4% YoY). While revenue grew, overseas operating profit fell 18% due to marketing costs. A moderate negative impact of approximately 5% is estimated due to the decline in net profit.
Announcement of Q1 2026 financial results reporting an 11% YoY increase in revenue to KRW 40.0 billion and a swing to operating profit of KRW 800 million; a 5-10% price impact is estimated due to the turnaround. scheduled
Announcement of the accelerated timeline for Imeroprubart (HL161ANS) registrational study results in D2T RA to H2 2026; a ~5% price increase is estimated from earlier commercialization. scheduled
Amorepacific Corp announced its Q1 2026 earnings on April 29, 2026, with consolidated revenue of KRW 1.136 trillion (+6.4% YoY) and operating profit of KRW 126.7 billion (+7.6% YoY), slightly exceeding market expectations. Growth was driven by derma brands and overseas expansion.
Hanwha Group entered South Korea's top 5 largest business conglomerates by fair trade asset size for the first time on April 29, 2026, driven by growth in its defense and energy businesses. Low importance is assigned as this reflects long-term growth rather than immediate price volatility.
Announced on April 29, 2026, a plan to dispose of treasury stock worth approximately KRW 33.56 million on May 4, 2026, for employee stock grants. The impact is estimated to be minimal (around 1%) given the very small transaction size relative to market capitalization, scheduled.
Directors Tian Zhoushan and Li Dakui retired from the board on 2026-04-29; Low importance justified by minimal expected market impact from board personnel changes, scheduled.
Ex-dividend date for the 2025 final cash dividend of RMB 2 per 10 shares on April 29, 2026; approved at the AGM on April 16, 2026. The dividend amount suggests a >=1% price impact scheduled.
Announced Q1 2026 product revenue exceeded RMB 3.8 billion, a year-over-year increase of over 50%, driven by strong performance of its oncology and general biomedicine portfolios. The stock rose over 4.5% on the news.
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
The B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 was granted Breakthrough Therapy Designation by China's NMPA for the treatment of advanced castration-resistant prostate cancer.
China's CDE proposed including IBI363, a first-in-class PD-1/IL-2α bispecific antibody, for breakthrough therapy designation for the treatment of advanced MSS/pMMR colorectal cancer. This regulatory progress is estimated to have a medium market impact (≥5%).
Ivonescimab (PD-1/VEGF bispecific antibody) received multiple Class I recommendations in the 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) on 2026-04-28. Market impact is estimated at Medium because of the drug's significant role in the first-line NSCLC market.
Received a high credit rating of 'AA-' with a 'Stable' outlook from major Korean credit rating agencies, citing business stability and improved financial structure.
Announced the presentation of 9 anti-cancer new drug candidate studies at the American Association for Cancer Research (AACR) 2026, showcasing R&D capabilities in next-generation modalities like TPD, mRNA, and ADCs.
Announced unaudited Q1 2026 financials for subsidiary CSPC Innovation on 2026-04-27, showing a 40.82% revenue increase but a 248.88% widening of net loss; a ~5% price impact is estimated due to mixed subsidiary performance.
Yuanta Securities raised its target price by 42.1% to KRW 540,000, for which medium importance is estimated as significant revisions typically drive >5% price impact, forecasted.
2026 growth targets announcement on April 26, 2026, maintaining a 30% growth goal for sales and profit expected. Low importance estimated as targets align with existing growth trends.
Analysts forecast strong Q1 2026 earnings, expected to exceed market consensus, driven by client diversification and robust exports; multiple securities firms raised their target price, with medium impact estimated as earnings growth is a key driver forecasted.
Announced on 2026-04-24 that its high-selectivity KAT6 inhibitor (SYH2095 tablet) received FDA IND approval; a ~1% price impact is estimated as this is an early-stage regulatory milestone.